Biocon Ltd

Biocon Other Announcement

Biocon Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing details holdings across promoter, institutional, and public categories.

Biocon Regulatory Approval

Biocon received EMA approval for a new insulin fill finish line in Malaysia. Supplies to the European market are expected to commence from Q2FY27.

Biocon Annual General Meeting

Biocon Limited convened its 48th AGM for August 6, 2026. Key agenda items include a 10% dividend declaration and adoption of a new long-term incentive plan.

Biocon Annual Report

Biocon Limited has released its Integrated Annual Report for FY 2025-26. The company's 48th Annual General Meeting is scheduled for August 06, 2026.

Biocon Capital Structure Change

Mylan Inc. sold 9,19,67,019 equity shares of Biocon Limited, representing a 5.64% stake. The transaction was executed via an open market sale.

Biocon Business Update

Biocon announced the publication of Phase III clinical data supporting the effectiveness of its biosimilar Yesafili™. The data reinforces clinical equivalence ahead of its US launch.

Biocon Capital Structure Change

Biocon allotted 8.78 million equity shares via preferential issue at Rs. 376.41 per share. The Rs. 330.73 Crore fund-raise increased paid-up capital.

Value

₹330.7 Cr

Biocon Merger & Restructuring Worth ₹330.7 Cr

Biocon Limited acquired remaining stakes in Biocon Biologics via a Rs. 330.73 Crore share swap. BBL is now a wholly-owned subsidiary after 87.86 lakh shares were allotted.

Value

₹330.7 Cr

Biocon Announces New Order Win

Biocon’s subsidiary will supply insulin to Duopharma Biotech under Malaysian MoH contracts worth over MYR 225 million. The three‑year and two‑year deals expand Biocon’s presence in Malaysia’s diabetes market.

Biocon Announces New Order Win

Biocon will supply insulin to Duopharma under contracts worth over MYR 225 million. The partnership strengthens its diabetes care footprint in Malaysia.

Biocon Acquisition Worth ₹5.48 Cr

Biocon invested Rs.5.48 Crore for a 37.77% stake in Ampin C&I Power Twelve, a solar SPV. This supports its renewable energy goals and reduces carbon footprint.

Value

₹5.48 Cr

Biocon Annual General Meeting

Biocon Limited announced the successful passage of several postal ballot resolutions. Key approvals include executive appointments, remuneration revisions, and a preferential issuance of equity shares.

Biocon Earnings Call: Key Takeaways

Biocon's June 2026 presentation highlights its transformation into an integrated biopharma leader following the Viatris acquisition. FY26 revenue reached $1,924M (₹16,927 Cr) with a 22% EBITDA margin.

Biocon Annual General Meeting

Biocon Limited has initiated a postal ballot for shareholder approval of a preferential equity share issuance. This corporate action seeks authorization for consideration other than cash.

Biocon Annual General Meeting

Biocon issued a corrigendum to its May 07 postal ballot notice regarding a ₹330.73 Crore preferential issue. It revises floor price, issue price, and allotment details.

Value

₹330.7 Cr

Biocon Earnings Call: Key Takeaways

Biocon Q4 FY26 reported 10% YoY revenue growth (ex-lenalidomide) with integration of biosimilars/generics complete. Focus shifts to execution and deleveraging.